Bio-Rad Laboratories BIO

$369.14 +13.57 (3.82%)

Valuation

Market cap
9,507,231,000
Revenue TTM
$2,583,200,000
Net income TTM
$759,900,000
PE ratio
40.70
Forward PE
40.70
Profit margin
29.42%
Debt to equity
0.17

Trading

Volume
223,600
Avg volume
277,390
Day's range
$357.28 – $369.40
Shares out
26,738,000
Stochastic %K
44%
Beta
1.07
Analysts
Sell
Price target
$350.60

Price

Company profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, a...

Show more

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Industry
Medical Devices
Sector
Healthcare
Phone
510 724 7000
Website
https://www.bio-rad.com
Address
1000 Alfred Nobel Drive, Hercules, United States

Latest news

No headlines yet.

Stocktwits

Bogwood Aug 10, 8:42 PM
$IMDX At first glance I'm not a fan of this report: no $BIO agreement detail, no registry site update numbers, and no Q3 IQ kit sales. They wouldn't newly announce the heart KOL event if they weren't confident in the timeline and imminent approval, though. Tomorrow's price depends so much on Josh and Andrea's sentiment during this call
1 replies
vane77 Aug 5, 6:15 PM
$BIO Upgraded still going up big!
0 replies
StocktwitsEarnings Aug 4, 8:23 PM
$BIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $13.89 up 19.02% YoY • Reported revenue of $651M down -0.09% YoY
0 replies
Bogwood Aug 4, 3:23 PM
$IMDX I try not to think too much into this, but I think reiterating 8/10 for the 10-Q is good news. They haven't been to any investor conferences for over a quarter now implicating the "quiet period" before the decision and $BIO agreement, but now they are the day after earnings... Why would I want to do a 1x1 if there's no news and they can't talk about the FDA timeline? Doesn't make sense, so I'm leaning bullish on the report and imminent approval, on track to 8/20 or even earlier. I'm not buying more before the readout as it's such a frizzy thought, though
0 replies
JFDI Jul 27, 6:15 PM
$BIO good look, too thin
0 replies
JackDarwin Jul 24, 10:36 AM
$BIO Open = Low with gap candle.
0 replies
TheOne_24 Jul 16, 11:17 AM 0 replies
SuperGreenToday May 19, 4:21 AM
$BIO Share Price: $282.01 Contract Selected: Dec 18, 2026 $290 Calls Buy Zone: $23.20 – $28.67 Target Zone: $37.07 – $45.30 Potential Upside: 51% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 replies